A-Alpha Bio

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the worlds largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washingtons Institute for Protein...

Drug discovery,protein engineering,synthetic biology,immunocytokines,molecular glues,oncology,and protein-protein interactions

A-alpha bio operates in the Biotechnology research industry.

A-alpha bio's revenue is 11m - 100m

A-alpha bio has 51 - 200 employees.